NCT04157881View on ClinicalTrials.gov

A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 3, 2020

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Atrial FibrillationVenous Thromboembolism
Interventions
DRUG

RABEprazole 20 Mg Oral Delayed Release Tablet

Absorption of APO-Dabigatran measured with and without influence of rabeprazole

DRUG

APO-Dabigatran 150mg

Absorption of APO-Dabigatran post single dose

Trial Locations (1)

L8L 2X2

The Population Health Research Institute, Hamilton

Sponsors
All Listed Sponsors
collaborator

Hamilton Health Sciences Corporation

OTHER

lead

Population Health Research Institute

OTHER